Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18193812rdf:typepubmed:Citationlld:pubmed
pubmed-article:18193812lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18193812lifeskim:mentionsumls-concept:C0027765lld:lifeskim
pubmed-article:18193812lifeskim:mentionsumls-concept:C0001645lld:lifeskim
pubmed-article:18193812pubmed:dateCreated2008-1-15lld:pubmed
pubmed-article:18193812pubmed:abstractTextThe role of beta blockers (especially of propranolol, which has been most frequently used) in prophylaxis of migraine and treatment of essential tremor has been evidenced. These are two exceptionally common neurological entities, therefore detailed insight into indications, dose range and side-effects is necessary. Thus, the optimum therapeutical doses of propranolol for prophylaxis of migraine range from 160-240 mg a day, and for treatment of essential tremor from 240-320 mg a day, which, based on our experiences from practice, indicates that a large number of patients is receiving suboptimal doses, being, consequently, devoid of the best therapeutical effect.lld:pubmed
pubmed-article:18193812pubmed:languagesrplld:pubmed
pubmed-article:18193812pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18193812pubmed:citationSubsetIMlld:pubmed
pubmed-article:18193812pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18193812pubmed:statusMEDLINElld:pubmed
pubmed-article:18193812pubmed:monthJunlld:pubmed
pubmed-article:18193812pubmed:issn0370-8179lld:pubmed
pubmed-article:18193812pubmed:authorpubmed-author:Kosti?V SVSlld:pubmed
pubmed-article:18193812pubmed:issnTypePrintlld:pubmed
pubmed-article:18193812pubmed:volume120 Suppl 4lld:pubmed
pubmed-article:18193812pubmed:ownerNLMlld:pubmed
pubmed-article:18193812pubmed:authorsCompleteYlld:pubmed
pubmed-article:18193812pubmed:pagination54-8lld:pubmed
pubmed-article:18193812pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:18193812pubmed:meshHeadingpubmed-meshheading:18193812...lld:pubmed
pubmed-article:18193812pubmed:meshHeadingpubmed-meshheading:18193812...lld:pubmed
pubmed-article:18193812pubmed:meshHeadingpubmed-meshheading:18193812...lld:pubmed
pubmed-article:18193812pubmed:meshHeadingpubmed-meshheading:18193812...lld:pubmed
pubmed-article:18193812pubmed:year1992lld:pubmed
pubmed-article:18193812pubmed:articleTitle[Beta blockers in the treatment of neurological disorders].lld:pubmed
pubmed-article:18193812pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18193812pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:18193812pubmed:publicationTypeReviewlld:pubmed